MDRX - Veradigm Inc.
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 12.25 |
| Open | 12.27 |
| Bid | 11.94 x 1400 |
| Ask | 11.95 x 900 |
| Day's Range | 11.83 - 12.17 |
| 52 Week Range | 11.57 - 19.77 |
| Volume | |
| Avg. Volume | 1,085,717 |
| Market Cap | 1.298B |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | 13.50 |
| EPS (TTM) | 0.88 |
| Earnings Date | Jun 14, 2023 - Jun 16, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Oct 07, 2008 |
| 1y Target Est | 18.95 |
Fair Value
Related Research
- Business Wire
Veradigm Payerpath™ Rated #1 End-to-End Revenue Cycle Management (RCM) Software
CHICAGO, June 08, 2023--Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced that Black Book, a healthcare-centric market research and public opinion research and consulting company, has honored Veradigm Payerpath with the highest ranking in its End-to-End RCM Software Technology, Physician Practices & Ambulatory Facilities/Groups category for 2023.
- Business Wire
Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing
CHICAGO, May 19, 2023--Veradigm Inc. (Nasdaq: MDRX) announced today that, as expected, it received a notice from Nasdaq indicating that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) because the Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2022 (the "Form 10-K") and Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the "Form 10-Q"). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic
Simply Wall St.Investors Will Want Veradigm's (NASDAQ:MDRX) Growth In ROCE To Persist
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
- Simply Wall St.
Veradigm Inc. (NASDAQ:MDRX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
It is hard to get excited after looking at Veradigm's (NASDAQ:MDRX) recent performance, when its stock has declined 32...
Business WireVeradigm Network Solution Practice Fusion EHR Receives Top Ranking
CHICAGO, March 23, 2023--Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Practice Fusion first for Allergy and Immunology and second for Rheumatology within its 2023 Ambulatory EHR by Physician Specialty category.
Business WireVeradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing, Provides Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results
CHICAGO, March 22, 2023--Veradigm Inc. (NASDAQ: MDRX), announced today an update on the status of its year-end audit procedures for 2022. As the Company disclosed on February 28, 2023, due to an expansion of year-end audit procedures, the Company filed with the SEC a Form 12b-25, extending the due date of its annual report on Form 10-K by 15 days, to allow for completion of those procedures.
- Simply Wall St.
Despite shrinking by US$50m in the past week, Veradigm (NASDAQ:MDRX) shareholders are still up 139% over 3 years
Veradigm Inc. ( NASDAQ:MDRX ) shareholders might be concerned after seeing the share price drop 26% in the last...
Business WireVeradigm Practice Management Ranks First in Practice Management Solutions from Black Book™ Research
CHICAGO, March 14, 2023--Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Veradigm Practice Management first for its 2023 Practice Management Solutions, 50+ Physician Groups category.
Business WireVeradigm Inc. Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results
CHICAGO, February 28, 2023--Veradigm Inc. (NASDAQ: MDRX), announced today that in conjunction with its year-end audit procedures it has detected certain internal control failures related to revenue recognition that have occurred over the prior six quarters, resulting in a mis-statement to reported revenues during those periods. As a result, the Company and its external auditors need to expand procedures and are filing with the SEC a Form 12b-25, extending the due date of the Company’s Form 10-K
Business WireVeradigm Announces Two New Appointments to Its Board
CHICAGO, February 22, 2023--Susan Rodriguez and Shih-Yin Ho, MD have been named to the Board of Directors of Veradigm Inc. (NASDAQ: MDRX). With their combined experience in the pharmaceutical industry, digital health, and healthcare, together they bring a wealth of experience to Veradigm, to help build upon the company’s vision of transforming health, insightfully.
Business WireVeradigm to Release Fourth Quarter and Fiscal Year 2022 Financial Results March 1
CHICAGO, February 21, 2023--Veradigm®, Inc. (NASDAQ: MDRX), will report its financial results for the three and twelve months ended December 31, 2022 after the close of the regular stock market hours on Wednesday, March 1, 2023. Veradigm management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day.
Business WireVeradigm and HealthVerity Collaborate to Advance Real-World Evidence and Care for Patients with Cardiovascular Disease and Diabetes
CHICAGO & PHILADELPHIA, February 13, 2023--Veradigm®, a leading provider of healthcare data and technology solutions (NASDAQ: MDRX), and HealthVerity®, a leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data, today announced a collaboration that will advance real-world research and improve patient care for those with cardiovascular disease and diabetes. The collaboration makes Veradigm’s data from their Cardiovascular and Metabolic Registries fully interoperable with d
Business WireVeradigm FollowMyHealth Named Most Improved Software Product by KLAS
CHICAGO, February 09, 2023--Veradigm Inc. (NASDAQ: MDRX), announced today that Veradigm FollowMyHealth (formerly FollowMyHealth), a leading mobile-first patient engagement platform, was recently recognized by KLAS, a prominent healthcare solution evaluator, as Most Improved Software Product in its 2023 Best in KLAS report.
- Simply Wall St.
What Does Veradigm Inc.'s (NASDAQ:MDRX) Share Price Indicate?
While Veradigm Inc. ( NASDAQ:MDRX ) might not be the most widely known stock at the moment, it led the NASDAQGS gainers...
Business WireVeradigm® Network EHR Data is Now Available in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) Format
CHICAGO, January 30, 2023--Veradigm (NASDAQ: MDRX) announced today that Veradigm Network EHR Data is now available within the OMOP CDM format. Veradigm Network EHR is a complete statistically deidentified dataset containing three integrated EHR sources. This source dataset is now available in the OMOP CDM version 5.3.1.
ZacksSyneos Health (SYNH) Signs New Partnership With Cryoport
Syneos Health (SYNH) inks a partnership with Cryoport to deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers.
- News Direct
Sector Spotlight: HealthCare Software Stocks For 2023
Companies that develop and market software solutions for the healthcare sector are referred to as "medical management software stocks." Electronic health records (EHRs), practice management systems...
BenzingaVeradigm Takes Action with FY23 Outlook and Major Share Buyback Initiative
Veradigm Inc (NASDAQ: MDRX) shares are trading higher Wednesday after the company announced a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock. The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock, which was almost fully utilized in 2022. In the fourth quarter of 2022, Veradigm repurchased $57 million of its common stock, bringing its full-year tota
Business WireVeradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fiscal 2023
CHICAGO, January 11, 2023--Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today that its Board of Directors has approved a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock. The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock which was almost fully utilized during 2022. In the fourth quarter of 2022 Veradigm
Business WireVeradigm Building Momentum Across All Markets
CHICAGO, January 10, 2023--Veradigm Inc. (NASDAQ: MDRX) reports today strong fourth quarter new business results across all markets including the payer, life science, and provider markets.
Business WireVeradigm Announces Strategic Investment in Holmusk
CHICAGO, January 09, 2023--Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk’s $45 million series B financing round. The round was led by Veradigm, with participation from current investors including Heritas Capital, Health Catalyst Capital, Novartis (dRx Capital), and Northwell Holdings, the venture investment arm of Northwell Health
- Simply Wall St.
An Intrinsic Calculation For Veradigm Inc. (NASDAQ:MDRX) Suggests It's 49% Undervalued
In this article we are going to estimate the intrinsic value of Veradigm Inc. ( NASDAQ:MDRX ) by taking the expected...
Business WireVeradigm to Present at the 2023 J.P. Morgan Healthcare Conference
CHICAGO, January 06, 2023--Veradigm Inc. (Nasdaq:MDRX), formerly Allscripts Healthcare Solutions Inc., announced today that Rick Poulton, Veradigm Chief Executive Officer, will present at the 2023 J.P. Morgan Healthcare conference on Wednesday, January 11, 2023 at 3:45 PST.
Business WireAllscripts Announces Corporate Name Change to Veradigm Inc.
CHICAGO, January 03, 2023--Allscripts Healthcare Solutions, Inc. announced today that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand during 2022, and Allscripts will now formally be known as Veradigm.
Zacks3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.